And the femur fractures have been well-documented.
. . .The U.S. Supreme Court has refused to hear an appeal filed by Merck (NYSE:MRK) that attempted to block a large lawsuit from hundreds of women who argue that the company's osteoporosis drug Fosamax (alendronate) led to the development of atypical thighbone fractures.
The high court's denial of certiorari means that a failure-to-warn lawsuit that includes more than 500 women can move forward in a New Jersey federal court.
Merck was seeking to overturn a federal appellate court decision that cleared the way for the case to proceed. . . .
Now you know -- still off grin in the San Juans. Be excellent to one another!
नमस्ते
No comments:
Post a Comment